About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

Perseus Proteomics Inc.(4882) Summary

4882
TSE Growth
Perseus Proteomics Inc.
433
JPY
-27
(-5.87%)
Apr 4, 3:30 pm JST
2.96
USD
Apr 4, 2:30 am EDT
Result
PTS
outside of trading hours
410.2
Apr 4, 8:02 pm JST
Summary Chart Historical News Financial Result
PER
PBR
4.09
Yield
ー%
Margin Trading Ratio
816.02
Stock Price
Apr 4, 2025
Opening Apr 4, 9:03 am
445 JPY 3.04 USD
Previous Close Apr 3
460 JPY 3.12 USD
High Apr 4, 9:03 am
451 JPY 3.08 USD
Low Apr 4, 1:42 pm
398 JPY 2.73 USD
Volume
3,538,100
Trading Value
1.49B JPY 0.01B USD
VWAP
421.55 JPY 2.89 USD
Minimum Trading Value
43,300 JPY 296 USD
Market Cap
6.38B JPY 0.04B USD
Number of Trades
4,527
Liquidity & Number of Trades
As of Apr 4, 2025
Liquidity
High
1-Year Average
2,929
1-Year High Jul 25, 2024
20,021
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 28, 2025 5,500 3,387,100 615.84
Mar 21, 2025 87,800 3,505,600 39.93
Mar 14, 2025 0 3,565,900
Mar 7, 2025 0 3,473,100
Feb 28, 2025 0 3,666,800
Company Profile
Perseus Proteomics Inc. is a biotech venture company specializing in the development of high-performance antibody drugs and research reagents targeting cancer.
Sector
Pharmaceuticals
Perseus Proteomics Inc. is a biotech venture company that leverages its academic drug discovery network originating from the University of Tokyo to conduct research and development of antibody drugs. Utilizing proprietary antibody acquisition and engineering technologies, the company is advancing the development of therapeutic antibodies targeting cancer and hematological diseases. Its main pipeline includes PPMX-T002, a radioisotope-labeled antibody targeting cadherin 3, and PPMX-T003, an antibody targeting transferrin receptor 1. The company's revenue is derived from upfront payments from out-licensing drug candidates to domestic and international pharmaceutical companies, milestone payments based on development progress, and royalty income as a percentage of sales after market launch.